Materials and Methods Animals. 8-12-wk-old female DBA/2 mice were obtained from The Jackson Laboratories, Bar Harbor, ME. All mice were fed Purina mouse chow and given acidified tap water ad libitum . They were housed in a temperature-controlled room with a cycle of 12 h of light and 12 h of dark.
Tumor Cells. The L5178Y cell line is a nonmetastatic T cell lymphoma induced in DBA/2 mice with methylcholanthrene (1) .
Culture Medium. Eagle's MEM was supplemented with 10% FCS, sodium pyruvate (1 mM), nonessential amino acids (0.1 MM), L-glutamine (2 mM), 15 mM Hepes, sodium bicarbonate (1 .125 g/liter) and 50 Ag/ml gentamycin sulfate (Schering Corp., Kenilworth, NJ) .
Establishment of the L5178Y Tumor-dormant State. This procedure has been described (1) . Briefly, 105 in vivo-passaged L5178Y cells were implanted s.c. on the mid-ventral surface of DBA/2 mice. 7-10 d later, the resultant 0.5-1 .0 cm diam nodule was surgically excised, and 7 d later, mice were challenged i.p. with 5 X 104 L5178Y cells .
Partial Peritoneal Lavage (PPL). ' Mice received an i.p. injection of 2.5 ml of sterile pyrogen-free PBS, and the abdomen was massaged thoroughly to mix the PBS with the peritoneal contents. The mice were then lightly anesthetized with ether and restrained on a board, ventral side upward . A small area of the ventral surface was shaved, and 0.4-2 ml of the PBS was removed from the peritoneal cavity with a 5 ml syringe fitted with a 25-gauge needle . The volume removed from each sampling was recorded. The recovered peritoneal cells (PC) were pelleted and resuspended in the same volume of MEM .
Serial End-point Dilution Assay (SEPD)for Counting Tumor Cells (9) . Single-cell suspensions of peritoneal cell populations containing tumor cells were prepared from tumordormant mice. 100 j,l of MEM was added to each well of a 96-well flat-bottomed microtiter plate (Costar, Cambridge, MA) . 100 jul of each cell suspension was then added to the first well of each row, and a series of twofold dilutions was made through 24 wells. Each PC suspension was titrated in quadruplicate . The plates were incubated at 37°C in a humidified 5% C02 atmosphere and examined microscopically after 3 and 14 d incubation for tumor cell growth . Wells containing the highest dilution of each cell suspension that yielded positive tumor cell growth were identified, and the number of tumor cells in each initial cell suspension was calculated.
Classification of Tumor-dormant Mice. Immunized and challenged mice were classified as tumor-dormant if the number of tumor cells in the peritoneal cavity on the 25th d after L5178Y cell challenge days post challenge ; as determined by PPL and the SEPD assay, was 1-2 X 105. Tumor-dormant mice were classified as "tumor-emerging" when the number of tumor cells was >2 X 105 and <10'. Tumor-dormant mice were classified as "tumor-emergent" when the number of tumor cells in the peritoneal cavity was >10'. Tumor-dormant mice whose peritoneal cells yielded tumor cell growth when placed in culture at 4 X 105 cells/well in a 96-well microtiter plate are referred to as "in vitro tumorprogressor" tumor-dormant mice. Mice whose peritoneal cells yielded significantly fewer tumor cells after 7 d culture as compared with the inception of culture are referred to as "in vitro tumor-regressor" tumor-dormant mice.
Complete Peritoneal Lavage (CPL). Mice were killed by cervical dislocation, and the PC were removed in two successive 5-ml peritoneal washouts with PBS . The PC were pelleted by centrifugation, resuspended in 4 ml MEM, and counted by hemocytometer . This technique recovered >99% of the PC (9) .
In Vitro Tumor-dormant Peritoneal Cell System. Tumor-dormant mice were killed and CPLs were performed . The recovered PC were brought to a concentration of 4 X 10 6 cells/ml . A volume of 0.5 ml of the PC suspension from each mouse was used for quantitation of tumor cells using the SEPD assay, and the numbers of tumor cells ?er 4 X 105 PC was calculated. 1/1o ml of the remaining PC suspension (containing 4 X 10 PC) from each mouse was added to individual wells of a 96-well microtiter flat-bottomed culture plate (Costar) . The wells were then divided into sets as indicated in the text, and the wells of each set received 0.1 ml of MEM, PGE2, or indomethacin, depending on the experimental design . The plates were incubated for 7 d at 37°C. The cells in the wells were then suspended and the tumor cells were quantitated by the SEPD assay and compared with the number of tumor cells calculated to be in the wells at the start of the cultures.
In Vitro PC Culture Supernatant PGE2 RIA. Peritoneal cells were removed from individual tumor-dormant mice and the number of tumor cells per 4 X 105 PC for each mouse was determined by SEPD assay. Cultures were then prepared as described in the previous section. After 7 d incubation at 37'C, the cell-free supernatants were removed and tested for PGE2 by RIA (' 25 I-PGE2 RIA kit purchased from New England Nuclear, Boston, MA) . This assay could measure as little as 0 .13 pg/ml PGE2. The cells from the wells supplying the supernatants were then suspended, and the number of tumor cells in each suspension was quantitated by the SEPD assay. The number of tumor cells in each well at the beginning and end of culture was then compared, and each well was classified as yielding tumor cell growth or no growth .
Separation of Nonadherent PC. Nonadherent PC were separated from whole PC by adherence to plastic petri dishes.
PGE2 or Indomethacin Preparation. PGE2 (Upjohn Co., Kalamazoo, MI) and Indomethacin (Sigma Chemical Co., St. Louis, MO) were dissolved in 100% ethanol in a concentration of 10 m /ml as stock solution and kept in a -20°C freezer until used. The working solution, 10-M, was prepared by dilution in PBS or MEM .
In Vivo Protocol to Determine Effects of PGE2 or Indomethacin on Tumor-dormant State. The protocol illustrated in Fig . 1 was used. A PPL was performed on all L5178Y cell-immunized and challenged mice 25 d after L5178Y cell challenge . The number of tumor cells in each lavage was determined by the SEPD assay, and mice were classified as tumor-dormant on the basis of the number of tumor cells in their peritoneal cavity (see section on classification of tumor-dormant mice) . The tumor-dormant mice were then divided into groups, with each group having equal numbers of mice with comparable tumor burdens . The groups were then treated with PGE2 i.p . for 10 d, or with Indomethacin as indicated in the text. 4 d after the end of PGE2 treatment, or as indicated in the indomethacin experiments, the mice were killed and CPLs were performed . 10% of the PC from each mouse was used to quantitate the number of tumor cells in the lavage, and the remaining PC were placed in culture flasks at a low cell/surface area ratio to minimize cell-cell contact and to permit a single tumor cell to grow if present . The tumor cell numbers in each mouse before and after treatment were then compared.
Results
Effect of PGE2 on L5178Y Tumor-dormant State. To determine whether the PGE 2 produced by peritoneal macrophages in tumor-dormant mice before formation of ascitic tumors is responsible for termination of the tumor-dormant state, we administered 100 Wg of PGE 2 i .p. to mice daily for 10 d using the protocol shown in Fig . 1 . In this protocol, the number of tumor cells in each mouse was quantitated before treatment by PPL and SEPD assay, and after treatment by CPL and SEPD assay .
In the experiment shown in during such a 3-wk experimental period . In additional experiments, we found that tumor burdens increase in PGE2-treated tumor-dormant mice after only 5 d of treatment, as compared with ethanol-treated controls .
Tumor Cell Growth in Cultures ofPeritoneal Cellsfrom Tumor-dormant Mice. To study the mechanisms by which PGE2 produced its tumor cell growth-enhancing effect in tumor-dormant mice, we used an in vitro system . In this assay, described previously (1), 4 X 105 PC from a tumor-dormant mouse are placed in individual wells of a 96-well microtiter plate. We reported previously (1) that the small number of tumor cells present in these PC do not grow out during incubation at 37°C. Fig. 2 shows the growth of tumor cells in PC cultures prepared from a large number of tumor-dormant mice. PC from 26 tumor-dormant mice were harvested, the number of tumor cells per 4 X 105 PC in each mouse was quantitated by the SEPD assay, and the remaining PC were placed in wells of a 96-well microtiter plate, 4 X 105 cells/well, three wells/mouse. The plates were incubated for 7 d at 37°C, and the number of tumor cells in each well was quantitated by the SEPD assay. The mean number of tumor cells in the PC at inception and termination of culture for each mouse are shown in Fig. 2 . During the 7-d incubation period, tumor cells proliferated in the PC cultures prepared from some tumor-dormant mice, and the mice providing these PC are referred to as "in vitro tumor-progressor" mice. Tumor cells failed to grow out in the PC cultures prepared from other tumor-dormant mice, and the mice providing these PC are referred to as "in vitro tumor-regressor" mice . mine whether PGE2 would stimulate the growth of tumor cells in PC populations from in vitro tumor-regressor tumor-dormant mice, we added PGE2, at 10 -6 M, to 6 of 12 PC wells prepared from a number of tumor-dormant mice ; the other 6 wells from each mouse received ethanol-containing MEM . After 2, 4, and 7 d incubation, the cells in two of the PGE2-treated wells and in two of the untreated wells from each mouse were suspended, and the tumor cells in the suspensions were quantitated. Fig. 3 shows the effects of PGE2 on tumor cell growth in PC cultures prepared from an in vitro tumor-progressor mouse (mouse 1), and an in vitro tumor-regressor mouse (mouse 2). In mouse 1, tumor cells increased in number in the ethanol-treated control wells, and PGE2 had no effect on this tumor cell growth . In mouse 2, tumor cells decreased in number during the 7-d incubation period in the control wells, and the addition of PGE2 resulted in rapid tumor cell growth at a rate equal to the rate of growth of tumor cells in the cultures prepared from mouse 1 . Similar results have been found in many matched pairs of in vitro tumor-progressor and in vitro tumor-regressor tumordormant mice . In other experiments with pure tumor cell cultures, we found that PGE2 at 10 -6 M had no direct effect on the rate of tumor cell growth during 72 h incubation at 37 D C (data not shown) . These data suggest that PGE2 enhances tumor cell growth in PC cultures from in vitro tumor-regressor tumor-dormant mice by subverting the function of those host cells that normally restrain tumor cell growth .
Production ofPGE2 in PC Cultures from In Vitro Tumor-progressor Tumor-dormant
Mice. The parallel growth curves of tumor cells in the PGE2-treated and untreated wells of PC prepared from mouse 1 in the above experiment suggested that PGE2 was being produced in the untreated wells. To test this possibility, we prepared PC cultures from 17 tumor-dormant mice, one well/mouse, and after 7 d culture, we collected the cell-free supernatants from each well and measured the PGE2 in the supernatants by RIA. The PC in these wells were then suspended, and the number of tumor cells in each suspension was determined by the SEPD assay. As seen in Table II , there was an excellent correlation between the ability of tumor cells to proliferate and the amount of PGE2 in each well. However, there was no correlation between the total number of tumor cells in specific wells and the amount of PGE2 (data not shown) .
To identify the cell population that produces PGE2 in the PC cultures from in vitro tumor-progressor mice, and to exclude the possibility that these cultures contained PGE2-producing L5178Y cells, we transferred the PC from in vitro tumor-progressor cultures to tissue culture flasks . The L5178Y cells proliferated in the flasks and were passaged until no host cells remained . The supernatants of these tumor cell cultures were then tested for PGE2 and none was found . We can conclude from this experiment that PGE2 is produced by host cells rather than by tumor cells.
Effect of Indomethacin on the Tumor-dormant State. The ability of PGE2 to cause formation of ascitic tumors in tumor-dormant mice and promote tumor cell growth in vitro suggested that administration of an inhibitor of PGE2 synthetase, indomethacin, might eliminate tumor cells from tumor-dormant mice and inhibit tumor cell growth in vitro. To test this possibility, indomethacin was administered into the peritoneal cavity of tumor-dormant mice from Alzet miniosmotic pumps. These pumps, implanted subcutaneously on the ventral surface with a size PE 60 catheter leading into the peritoneal cavity, delivered a continuous amount of indomethacin, 50 Ag/d, or ethanol for 14 d; new pumps were not reimplanted in the 21-d-incubation mice. At selected days after implantation of the pumps, mice were killed and all PC were placed in culture, 10% of the PC in a SEPD assay, and the remaining PC in culture flasks at a low cell/culture surface area ratio to minimize cell-cell contact during the incubation period . As seen in Table III, /d i.p .) for the designated number of days, delivered at 0.6 ul/h by catheter from Alzet mini-osmotic pumps, which were implanted subcutaneously on the ventral surface. * The number of mice that had no recoverable tumor cells on cultivation of all PC at the end of the designated number of days of treatment divided by the total number of mice in each group. Mice. The production of PGE2 in cultures of PC from in vitro tumor-progressor tumor-dormant mice suggested that indomethacin added to such cultures at their inception might inhibit tumor cell growth . We therefore added indomethacin at 10 -5 , 10 -6 , and 10'-' M to wells of PC from in vitro tumor-progressor tumor-dormant mice, three wells per molarity, and 7 d later, we quantitated the tumor cells in the medium-and indomethacin-treated wells. These concentrations of indomethacin completely inhibit PGE2 production in PC cultures from in vitro tumor-progressor tumor-dormant mice (data not shown) . As seen in Fig. 4 , treatment of PC tumor-progressor cultures with indomethacin at 10' and 10-6 M inhibited tumor cell growth . In experiments with pure tumor cell cultures, we found that indomethacin at 10 -5 M had no direct effect on L5178Y cell growth (data not shown) . These data suggest that indomethacin inhibits tumor cell growth by preventing PGE2-mediated suppression of those host cells that normally restrain tumor cell growth . Dose Effect of PGE2 in Presence of Indomethacin on Tumor Cell Growth in PC Cultures Prepared from In Vitro Tumor-regressor Tumor-dormant Mice. We next evaluated the dose effect of PGE2 on the growth of tumor cells in PC cultures from in vitro tumor-regressor tumor-dormant mice . Indomethacin was added to each well in this experiment in order to inhibit endogenous PGE2 production . We first determined whether indomethacin would interfere with the tumor cell growth-enhancing effects of PGE2. As seen in Fig. 5 , PGE2 enhanced tumor cell growth . Indomethacin at 10 -6 M inhibited tumor cell growth, but had no inhibitory effect on the tumor cell growth-enhancing effect of 10 -6 M PGE2 . Fig. 6 shows the effect of various doses of PGE2 in the presence of 10-6 M indomethacin on tumor cell growth . The addition of 10 -5-10-7 M PGE2 stimulated tumor cell growth, and lower doses of PGE2 had no effect .
Identification of Host Cells that Restrain Tumor Cell Growth in PC Cultures from
In Vitro Tumor-regressor Tumor-dormant Mice. To identify the PC population that was responsible for the restraint on L5178Y cell growth in wells prepared from in vitro tumor-regressor mice, we separated the nonadherent peritoneal cells by a plastic-adherence step, and cultured both the complete and the nonadherent PC at high cell density. Since L5178Y cells are nonadherent, they remained in the nonadherent cell population . PGE2 was added to one-half of the number of wells of each PC population, and tumor cells were quantitated 7 d later by the SEPD assay.
As seen in Fig. 7 , tumor cell growth did not occur in the untreated complete PC cultures, but did occur when PGE2 was added to the cultures . In the untreated nonadherent PC cultures, tumor cells grew and PGE2 had no effect on tumor cell growth . These findings indicate that adherent cells are involved in the restraint on tumor cell growth . Yet to be determined is the role of the nonadherent PC in tumor cell growth restraint, and whether the adherent cells lyse or arrest the proliferation of tumor cells, or are required as accessory cells for nonadherent cells to restrain tumor cell proliferation .
Discussion
Prostaglandins of the E series are important regulators of many components of the immune response (11) . Among its other effects on the immune system, PGE2 has been reported to (a) inhibit the production of IL-2 (12, 13), (b) stimulate the production of suppressor T lymphocytes (14) (15) (16) , and (c) inhibit the clonal proliferation of B lymphocytes (17) . Macrophages produce large amounts of PGE2 on appropriate stimulation (18, 19) . This PGE2 can downregulate macrophage tumoricidal activity and may be an important self-regulating feedback mechanism for macrophage activation (20) (21) (22) . Macrophages from tumor-bearing mice produce increased amounts of PGE2 (23), and patients with various types of cancer have either increased levels of PGE2 and PGE2 metabolites (24) (25) (26) (27) , or have impaired immune responses that can be stimulated in vitro with indomethacin (28) . Administration of inhibitors of PG synthesis in mice has been found to retard or suppress tumor growth (29, 30) , and to improve cell-mediated immune functions when added to their spleen cells in vitro (29, 31) . However, in some tumors, such as B-16 melanoma, the major cyclooxygenase metabolite is PGD2 rather than PGE2, and inhibitors of PG synthesis produce tumor enhancement rather than tumor inhibition (32) .
To date, the effects of PGE2 and indomethacin on tumor growth have been evaluated in animal models in which tumor cells have either been induced or are growing after transplantation . Animal models of tumor dormancy are clinically relevant, in that small numbers of lethal tumor cells persist for prolonged periods of time without producing disease (33, 34) . Such models may be analogous to those patients who are in clinical remission after treatment of a primary tumor and who will develop a recurrent tumor. Likely examples of tumor-dormant states in human cancer are adenocarcinomas of the breast, which can grow out in the surgical scar tissue of a mastectomy as long as 50 yr after surgical removal of a histologically identical adenocarcinoma (35) , and malignant melanomas, which can grow out in the liver many years after removal of a uveal malignant melanoma (36, 37) . In this report we described the effects of PGE2 on tumor cell growth under conditions in which tumor cells were maintained in a tumor-dormant state. Previous evidence for the regulatory role of PGE2 in the L5178Y tumor-dormant system consists of our finding (6) that macrophages with increased immunosuppressive activity appear in the peritoneal cavity of tumor-dormant mice just before the appearance of ascitic tumors. These macrophages produce an immunosuppressive factor in vitro, now identified as PGE2 (our unpublished data), production of which is inhibited by indomethacin (7). Our demonstration that exogenous PGE2 stimulates formation of ascitic tumors in tumor-dormant mice provides further support for the hypothesis that PGE2, which is produced by peritoneal macrophages, terminates the tumor-dormant state.
We found that the PC cultures from in vitro tumor-progressor tumor-dormant mice (in which tumor cells proliferate progressively) produce more PGE2 than PC cultures from in vitro tumor-regressor tumor-dormant mice (in which tumor cells do not proliferate), and that the addition of PGE2 to tumor-regressor cultures converts them into tumor-progressor cultures. The variations in the ability of tumor cells to proliferate in PC cultures from tumor-dormant mice may reflect the variations in the duration of the tumor-dormant state among mice . It is possible, however, that the differences between tumor-regressor and tumor-progressor cultures may reflect ongoing cycles within an individual mouse, of macrophage activation and deactivation mediated by IFN--Y released from stimulated T cells, and by PGE2 released from activated macrophages. If this is so, then an individual mouse may go through cycles of tumor-progression and tumor-regression, the net result of which would be to maintain cytolytic or cytostatic control on tumor cell proliferation without killing all tumor cells. The demonstrations that indomethacin can both eliminate recoverable tumor cells from tumor-dormant mice and inhibit the proliferation of tumor cells in PC cultures from in vitro tumor-progressor tumor-dormant mice support the hypothesis that macrophage activation and deactivation is a feature of the tumordormant state, and that the inhibition of a suppressor of macrophage activation permits macrophages to kill all tumor cells.
The complete analysis of the L5178Y tumor-dormant model is limited by certain characteristics of the model. Since large numbers of peritoneal cells are required for the preparation of multiple PC cultures, it is necessary to kill the tumor-dormant mouse to obtain these cells. It is therefore not possible, in an individual mouse, to measure the changes in antitumor activity of peritoneal cell populations as that mouse proceeds through the tumor-dormant state towards termination. It is also not possible to compare one tumor-dormant mouse with another because of the large variations in the activity of the immune response and in the duration of the tumor-dormant state among mice that have been immunized and challenged with L5178Y cells at the same time.
The in vitro assay described here does provide a system in which the PC population of a single tumor-dormant mouse can be studied under controlled conditions . An important feature of this in vitro system is that it is quantitated in the same way as the in vivo model, e.g., by tumor cell proliferation . The tumor cell growth-enhancing effects of exogenous PGE2, when administered both in vivo and in vitro, and the tumor cell growth-inhibiting effects of indomethacin, when administered both in vivo and in vitro, support the validity of the in vitro system as a correlate of the in vivo model. This in vitro system, therefore provides an opportunity to evaluate the mechanisms that maintain and terminate the tumor-dormant state in vivo . Experiments to identify the mechanisms by which PGE2 and indomethacin produce their tumor cell growthenhancing and -inhibiting effects in tumor-dormant mice are in progress, and will constitute a subsequent paper in this series .
Our analysis of the L5178Y tumor-dormant model to date suggests that L5178Y cells are maintained in a tumor-dormant state by peritoneal macrophages and T lymphocytes. These cells are upregulated to a cytotoxic state by lymphokines released from L5178Y-stimulated helper T lymphocytes, and down-regulated to a noncytotoxic state by PGE2 released from activated macrophages. The PGE2 may downregulate macrophage cytolytic activity by acting directly on macrophages and downregulate T lymphocyte cytolytic activity either directly or indirectly by stimulating suppressor T lymphocytes. Both macrophages and cytolytic T lymphocytes may be downregulated before all tumor cells are killed, thereby permitting some tumor cells to escape lysis and persist in a tumordormant state. The tumor-dormant state may end when phenotypic variants of the L5178Y cells, which are less susceptible to immune lysis and less immunogenic than the L5178Y population used to initiate the tumor-dormant state, are selected by the immune response and become dominant in the peritoneal cavity of tumor-dormant mice (9, 10) . These poorly immunogenic tumor cell variants may not stimulate helper T lymphocytes to produce the regulatory lymphokines that are needed to maintain an effective anti-tumor cell response and maintain the tumor-dormant state. The L5178Y tumor-dormant model can be used to study immunoregulatory circuits that affect tumor growth, and to test therapeutic agents that can be given to patients who are in clinical remission after treatment of a primary tumor and who have a high statistical probability of developing a recurrent tumor.
Summary
Immunization and intraperitoneal challenge of DBA/2 mice with E5178Y lymphoma cells results in the suppression and maintenance of the L5178Y cells in a tumor-dormant state in the peritoneal cavity for many months . Cell-mediated immune responses involving lymphocytes and macrophages are involved in maintenance of the tumor-dormant state. Macrophages that have increased immunosuppressive activity and that produce increased amounts of PGE2 appear in the peritoneal cavity of tumor-dormant mice before the breakdown of the tumor-dormant state and formation of ascitic tumors .
We report here that the tumor-dormant state can be terminated with formation of ascitic tumors by treatment of tumor-dormant mice with PGE2 . Treatment with indomethacin results in inhibition of tumor cell growth and elimination of all recoverable tumor cells. Cultures of peritoneal cells (PC) from mice harboring L5178Y cells in a tumor-dormant state were used to analyze the PGE2 and indomethacin effects. Tumor cells did not grow out in the high-cell density PC cultures prepared from many tumor-dormant mice, but addition of PGE2 to these cultures resulted in tumor cell growth . The tumor cell growth that did occur in the PC cultures from some tumor-dormant mice was associated with PGE2 production by the associated host cells, and the addition of indomethacin to these cultures inhibited both PGE2 synthesis and tumor cell growth . Removal of plastic-adherent cells from the PC cultures eliminated the restraint on tumor cell growth . These experiments suggest that L5178Y tumor cells are maintained in a tumor-dormant state by host peritoneal cells, which are under PGE2 regulation .
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